HR and breast cancer: The aim of this review was also to highlight three of the most helpful and/or promising recent molecules in BC treatments to date (one for each main BC subtype: one for HER2+ patients (neratinib), one for TNBC patients (atezolizumab), and one for HR+/HER2− patients (palbociclib).